Arbitrators Allow Exiqon to Sell LNA Products to Pharmaceutical Market | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Arbitrators have sided with Exiqon, allowing it to market locked nucleic acid-based LNA amidites and LNA oligonucleotides to the pharmaceutical market, the Danish firm announced today.

The decision by an arbitration court ends proceedings initiated by Exiqon last year against Santaris Pharma in a dispute over the LNA products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.